Gaël Dournes1, David Grodzki1, Julie Macey1, Pierre-Olivier Girodet1, Michaël Fayon1, Jean-François Chateil1, Michel Montaudon1, Patrick Berger1, François Laurent1. 1. From the Center for Cardiothoracic Research of Bordeaux, University of Bordeaux, Bordeaux, France (G.D., P.O.G., M.F., M.M., P.B., F.L.); Inserm, Center for Cardiothoracic Research of Bordeaux, U1045, F-3300, 146 rue Léo Saignat, 33076 Bordeaux, France (G.D., P.O.G., M.F., M.M., P.B., F.L.); Department of Thoracic and Cardiovascular Imaging, Department of Respiratory Disease, Department of Functional and Respiratory Examination, Centre Hospitalier Universitaire (CHU) de Bordeaux, Pessac, France (G.D., J.M., P.O.G., M.M., P.B., F.L.); Department for Imaging of the Woman and Child, Pediatric Pneumology Unit, CHU de Bordeaux, Bordeaux, France (M.F., J.F.C.); CHU de Bordeaux, CIC 0005, Bordeaux, France (M.F.); and Department of Magnetic Resonance, Siemens Healthcare, Erlangen, Germany (D.G.).
Abstract
PURPOSE: To assess lung magnetic resonance (MR) imaging with a respiratory-gated pointwise encoding time reduction with radial acquisition (PETRA) sequence at 1.5 T and compare it with imaging with a standard volumetric interpolated breath-hold examination (VIBE) sequence, with extra focus on the visibility of bronchi and the signal intensity of lung parenchyma. MATERIALS AND METHODS: The study was approved by the local ethics committee, and all subjects gave written informed consent. Twelve healthy volunteers were imaged with PETRA and VIBE sequences. Image quality was evaluated by using visual scoring, numbering of visible bronchi, and quantitative measurement of the apparent contrast-to-noise ratio (CNR) and signal-to-noise ratio (SNR). For preliminary clinical assessment, three young patients with cystic fibrosis underwent both MR imaging and computed tomography (CT). Comparisons were made by using the Wilcoxon signed-rank test for means and the McNemar test for ratios. Agreement between CT and MR imaging disease scores was assessed by using the κ test. RESULTS: PETRA imaging was performed with a voxel size of 0.86 mm(3). Overall image quality was good, with little motion artifact. Bronchi were visible consistently up to the fourth generation and in some cases up to the sixth generation. Mean CNR and SNR with PETRA were 32.4% ± 7.6 (standard deviation) and 322.2% ± 37.9, respectively, higher than those with VIBE (P < .001). Good agreement was found between CT and PETRA cystic fibrosis scores (κ = 1.0). CONCLUSION: PETRA enables silent, free-breathing, isotropic, and submillimeter imaging of the bronchi and lung parenchyma with high CNR and SNR and may be an alternative to CT for patients with cystic fibrosis.
PURPOSE: To assess lung magnetic resonance (MR) imaging with a respiratory-gated pointwise encoding time reduction with radial acquisition (PETRA) sequence at 1.5 T and compare it with imaging with a standard volumetric interpolated breath-hold examination (VIBE) sequence, with extra focus on the visibility of bronchi and the signal intensity of lung parenchyma. MATERIALS AND METHODS: The study was approved by the local ethics committee, and all subjects gave written informed consent. Twelve healthy volunteers were imaged with PETRA and VIBE sequences. Image quality was evaluated by using visual scoring, numbering of visible bronchi, and quantitative measurement of the apparent contrast-to-noise ratio (CNR) and signal-to-noise ratio (SNR). For preliminary clinical assessment, three young patients with cystic fibrosis underwent both MR imaging and computed tomography (CT). Comparisons were made by using the Wilcoxon signed-rank test for means and the McNemar test for ratios. Agreement between CT and MR imaging disease scores was assessed by using the κ test. RESULTS: PETRA imaging was performed with a voxel size of 0.86 mm(3). Overall image quality was good, with little motion artifact. Bronchi were visible consistently up to the fourth generation and in some cases up to the sixth generation. Mean CNR and SNR with PETRA were 32.4% ± 7.6 (standard deviation) and 322.2% ± 37.9, respectively, higher than those with VIBE (P < .001). Good agreement was found between CT and PETRA cystic fibrosis scores (κ = 1.0). CONCLUSION: PETRA enables silent, free-breathing, isotropic, and submillimeter imaging of the bronchi and lung parenchyma with high CNR and SNR and may be an alternative to CT for patients with cystic fibrosis.
Authors: Robert P Thomen; Laura L Walkup; David J Roach; Nara Higano; Andrew Schapiro; Alan Brody; John P Clancy; Zackary I Cleveland; Jason C Woods Journal: Am J Respir Crit Care Med Date: 2020-07-15 Impact factor: 21.405
Authors: Andrew B Rosenkrantz; Kent Friedman; Hersh Chandarana; Amy Melsaether; Linda Moy; Yu-Shin Ding; Komal Jhaveri; Luis Beltran; Rajan Jain Journal: AJR Am J Roentgenol Date: 2015-10-22 Impact factor: 3.959
Authors: Nara S Higano; Andrew D Hahn; Jean A Tkach; Xuefeng Cao; Laura L Walkup; Robert P Thomen; Stephanie L Merhar; Paul S Kingma; Sean B Fain; Jason C Woods Journal: Magn Reson Med Date: 2016-03-12 Impact factor: 4.668
Authors: Li Feng; Jean Delacoste; David Smith; Joseph Weissbrot; Eric Flagg; William H Moore; Francis Girvin; Roy Raad; Priya Bhattacharji; David Stoffel; Davide Piccini; Matthias Stuber; Daniel K Sodickson; Ricardo Otazo; Hersh Chandarana Journal: J Magn Reson Imaging Date: 2018-09-25 Impact factor: 4.813